News | July 24, 2025
Dr Reddy's Laboratories reports 2% rise in Q1 net profit to Rs. 1,418 Cr
Revenue increased 11.4 per cent to Rs. 8,545 crore
Revenue increased 11.4 per cent to Rs. 8,545 crore
Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%
Upgrades 2025 full-year CDMO sales and margin outlook
The global TCIM market is expected to reach nearly US$ 600 billion by 2025
Treatment with XPro was well-tolerated and safe, even in the high risk ApoE4+/+ patient group, and ARIA-E or ARIA-H was not observed in any patients
Annual EBITDA margin expands by 170 basis points
Adjusted EBITDA positive at Rs. 3.1 crore despite investments in marketing, talent hiring and technology over the year
Akums invested Rs. 272 crore in capital expenditure during FY25
The revenue witnessed a growth of 7.80 per cent on a year-on-year basis at Rs. 2,959 crore
Adjusted Profit After Tax (PAT) for the year ended March 31, 2025 was at Rs. 1,389.4 crore
Subscribe To Our Newsletter & Stay Updated
